GSK’s bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B: London, UK Friday, February 27, 2026, 09:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results